Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C14H27O2.C6H14N2.Pt.H2O |
Molecular Weight | 782.014 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Pt++].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O
InChI
InChIKey=LWDBMUAJGMXQAY-GSEQGPDBSA-L
InChI=1S/2C14H28O2.C6H14N2.H2O.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;1H2;/q;;;;+2/p-2/t;;5-,6-;;/m..1../s1
Molecular Formula | C6H14N2 |
Molecular Weight | 114.1888 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C14H28O2 |
Molecular Weight | 228.3709 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Pt |
Molecular Weight | 195.084 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ds-pharma.com/ir/news/pdf/ene20091016.pdf
70 mg of miriplatin is suspended in 3.5 mL of
suspension vehicle for this drug, and administered
once a day through catheter inserted into hepatic
artery.
Administration of miriplatin-suspension ends when
tumor vessel is filled with the drug, provided that
the upper limit should be 6 mL per administration
(equivalent to 120 mg of miriplatin). An observation
period of 4 weeks or longer is required in the case of
repeated administration.
Route of Administration:
Intra-arterial
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10744050
Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:09:20 GMT 2023
by
admin
on
Sat Dec 16 05:09:20 GMT 2023
|
Record UNII |
75H6U03J2H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50179715
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
100000127453
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
250159-48-9
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
SUB33476
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
75H6U03J2H
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
23725065
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY | |||
|
m11894
Created by
admin on Sat Dec 16 05:09:20 GMT 2023 , Edited by admin on Sat Dec 16 05:09:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |